PT  - JOURNAL ARTICLE
AU  - Iturria-Medina, Yasser
AU  - Carbonell, Félix
AU  - Assadi, Atousa
AU  - Adewale, Quadri
AU  - Khan, Ahmed F.
AU  - Baumeister, Robert
AU  - Sanchez-Rodriguez, Lazaro
AU  - ,
TI  - NeuroPM toolbox: integrating Molecular, Neuroimaging and Clinical data for Characterizing Neuropathological Progression and Individual Therapeutic Needs
AID  - 10.1101/2020.09.24.20200964
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.24.20200964
4099  - http://medrxiv.org/content/early/2020/09/25/2020.09.24.20200964.short
4100  - http://medrxiv.org/content/early/2020/09/25/2020.09.24.20200964.full
AB  - There is a critical need for a better multiscale and multifactorial understanding of neurological disorders, covering from genes to neuroimaging to clinical factors and treatments effects. Here we present NeuroPM-box, a cross-platform, user-friendly and open-access software for characterizing multiscale and multifactorial brain pathological mechanisms and identifying individual therapeutic needs. The implemented methods have been extensively tested and validated in the neurodegenerative context, but there is not restriction in the kind of disorders that can be analyzed. By using advanced analytic modeling of molecular, neuroimaging and/or cognitive/behavioral data, this framework allows multiple applications, including characterization of: (i) the series of sequential states (e.g. transcriptomic, imaging or clinical alterations) covering decades of disease progression, (ii) intra-brain spreading of pathological factors (e.g. amyloid and tau misfolded proteins), (iii) synergistic interactions between multiple brain biological factors (e.g. direct tau effects on vascular and structural properties), and (iv) biologically-defined patients stratification based on therapeutic needs (i.e. optimum treatments for each patient). All models’ outputs are biologically interpretable. A 4D-viewer allows visualization of spatiotemporal brain (dis)organization. Originally implemented in MATLAB, NeuroPM-box is compiled as standalone application for Windows, Linux and Mac environments: neuropm-lab.com/software. In a “regular” workstation, it can analyze over 150 subjects per day, reducing the need for using clusters or High-Performance Computing (HPC) for large-scale datasets. This open-access tool for academic researchers may significantly contribute to a better understanding of complex brain processes and to accelerating the implementation of Precision Medicine (PM) in neurology.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe want to give a special thanks to Ms. Sheila Linden for her generous funding support to this project. This project was also undertaken thanks in part to the following funding awards to YIM: the Fonds de la Recherche en Sante du Quebec (FRQS) Research Scholars Junior 1, the Weston Brain Institute Rapid Response AD program 2018, and the New Investigator start-up grant from McGill University's Healthy Brains for Healthy Lives Initiative (Canada First Research Excellence Fund). In addition, dataset-2 collection and sharing for this project was funded by ADNI (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Access to ADNI data analyzed in this study was granted to first author Yasser Iturria Medina, after providing the requested project information to ADNI. Data was accessed via the LONI portal (https://ida.loni.usc.edu/login.jsp?project=ADNI&page=HOME). The study was conducted according to Good Clinical Practice guidelines, the Declaration of Helsinki, US 21CFR Part 50, Protection of Human Subjects, and Part 56, Institutional Review Boards, and pursuant to state and federal HIPAA regulations (adni.loni.usc.edu). All ADNI subjects and/or authorized representatives gave written informed consent at the time of enrollment for sample collection and completed questionnaires approved by each participating site Institutional Review Board (IRB). The authors obtained approval from the ADNI Data Sharing and Publications Committee for data use and publication, see documents http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Data_Use_Agreement.pdf and http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Manuscript_Citations.pdf, respectively.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are publicly available at the Gene Expression Omnibus (GEO; ncbi.nlm.nih.gov/geo/, accession number GSE44772) and the Alzheimer's Disease Neuroimaging Initiative (ADNI; adni.loni.usc.edu). https://www.neuropm-lab.com/neuropm-box.html